Molecular Network Analysis of the Urinary Proteome of Alzheimer’s Disease Patients
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background/Aims: The identification of predictive biomarkers for Alzheimer’s disease (AD) from urine would aid in screening for the disease, but information about biological and pathophysiological changes in the urine of AD patients is limited. This study aimed to explore the comprehensive profile and molecular network relations of urinary proteins in AD patients. Methods: Urine samples collected from 18 AD patients and 18 age- and sex-matched cognitively normal controls were analyzed by mass spectrometry and semiquantified with the normalized spectral index method. Bioinformatics analyses were performed on proteins which significantly increased by more than 2-fold or decreased by less than 0.5-fold compared to the control (p < 0.05) using DAVID bioinformatics resources and KeyMolnet software. Results: The levels of 109 proteins significantly differed between AD patients and controls. Among these, annotation clusters related to lysosomes, complement activation, and gluconeogenesis were significantly enriched. The molecular relation networks derived from these proteins were mainly associated with pathways of lipoprotein metabolism, heat shock protein 90 signaling, matrix metalloproteinase signaling, and redox regulation by thioredoxin. Conclusion: Our findings suggest that changes in the urinary proteome of AD patients reflect systemic changes related to AD pathophysiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Mateos-Pérez, J. M., Evans, A. C., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11934 · Cited by 1,202
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70228-4 · Cited by 541
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506
Cataldo, A. M., Barnett, J. L., Berman, S. A., Li, J., Quarless, S., Bursztajn, S., Lippa, C., & Nixon, R. A. (1995) · Neuron · doi:10.1016/0896-6273(95)90324-0 · Cited by 379
An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer’s disease
Zhang, J., Chen, C., Hua, S., Liao, H., Wang, M., Xiong, Y., & Cao, F. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.10.024 · Cited by 376
Cited by
Urinary Biomarkers for Neurodegenerative Diseases
Seol, W., Kim, H., & Son, I. (2020) · Experimental Neurobiology · doi:10.5607/en20042 · Cited by 61
“For example, matrix metalloproteinase signaling, lipoprotein metabolism and heat shock protein 90 signaling pathways were related to AD [16].”
BackgroundQuantitative proteomics of synaptosome S‐nitrosylation in Alzheimer’s disease
Wijasa, T. S., Sylvester, M., Brocke‐Ahmadinejad, N., Schwartz, S., Santarelli, F., Gieselmann, V., Klockgether, T., Brosseron, F., & Heneka, M. T. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14870 · Cited by 41
Urinary Apolipoprotein C3 Is a Potential Biomarker for Alzheimer’s Disease
Watanabe, Y., Hirao, Y., Kasuga, K., Tokutake, T., Kitamura, K., Niida, S., Ikeuchi, T., Nakamura, K., & Yamamoto, T. (2020) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000509561 · Cited by 38
Self-citationWang, Y., Sun, Y., Wang, Y., Jia, S., Qiao, Y., Zhou, Z., Shao, W., Zhang, X., Guo, J., Zhang, B., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01324-4 · Cited by 34
“Watanabe et al. [39] identified a total of 1705 unique proteins in 18 AD and 18 controls while only 578 proteins were identified in at least half samples of either group.”
Background
Metadata
- Authors
- Watanabe, Y., Hirao, Y., Kasuga, K., Tokutake, T., Semizu, Y., Kitamura, K., Ikeuchi, T., Nakamura, K., & Yamamoto, T.
- Venue
- Dementia and Geriatric Cognitive Disorders Extra
- Publisher
- S. Karger AG
- Published
- 2019-02-08
- Volume
- 9
- Issue
- 1
- Pages
- 53-65
- ISSN
- 1664-5464 (ISSN-L)
- OpenAlex
- W2914078217
- Cited by
- 32
- References
- 14
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Network Analysis of the Urinary Proteome of Alzheimer’s Disease Patients. https://app.cochat.ai/papers/10.1159/000496100
- The paper
- Watanabe, Y., Hirao, Y., Kasuga, K., Tokutake, T., Semizu, Y., Kitamura, K., Ikeuchi, T., Nakamura, K., & Yamamoto, T. (2019). Molecular Network Analysis of the Urinary Proteome of Alzheimer’s Disease Patients. Dementia and Geriatric Cognitive Disorders Extra. https://doi.org/10.1159/000496100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.